Cargando…

Preliminary results of targeted prostate‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer

To investigate the feasibility and effectiveness of prostate‐specific membrane antigen (PSMA) imaging to make response assessment regarding novel hormone treatment and to predict the outcomes for metastatic castration‐resistant prostate cancer (mCRPC) patients. This retrospective study enrolled 68 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chang, Zhu, Yao, Su, Hengchuan, Xu, Xiaoping, Zhang, Yingjian, Song, Shaoli, Wang, Beihe, Ye, Dingwei, Hu, Silong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221296/ https://www.ncbi.nlm.nih.gov/pubmed/32163676 http://dx.doi.org/10.1002/cam4.2964

Ejemplares similares

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
por: Hu, Jason, et al.
Publicado: (2022)

Combination of body mass index and albumin predicts the survival in metastatic castration‐resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials
por: Pan, Jian, et al.
Publicado: (2021)

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data
por: Flaig, Thomas W., et al.
Publicado: (2015)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study
por: Barata, Pedro C, et al.
Publicado: (2023)

A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE
por: Payne, Heather, et al.
Publicado: (2021)

Src controls castration recurrence of CWR22 prostate cancer xenografts
por: Su, Bing, et al.
Publicado: (2013)

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Calderoni, Letizia, et al.
Publicado: (2023)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Evaluation of Radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer
por: Zhang, Jianping, et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Mohammadzadeh, Mohammad, et al.
Publicado: (2018)

Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
por: Gallyamov, Marat, et al.
Publicado: (2019)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)
por: Zhu, Yao, et al.
Publicado: (2020)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
por: Joshi, Amit, et al.
Publicado: (2020)

Author Correction: Evaluation of Radiation dosimetry of (99m)Tc-HYNIC-PSMA and imaging in prostate cancer
por: Zhang, Jianping, et al.
Publicado: (2020)

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
por: Nilsson, Sten
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6jlei5vipv2jmcikmsujicdm0s